KRAS and neoplasm: In summary, exploratory analyses of biomarker levels in baseline tumour tissue and plasma samples from patients with previously untreated mCRC stratified for KRAS mutation status,suggest a subgroup of patients with KRAS wild-type and higher than median levels of baseline Ang-2 in whom vanucizumab/mFOLFOX-6 was associated with a significant survival benefit of ~5.5 months over patients treated with bevacizumab/mFOLFOX-6.